Structure of HIV-1 Vpr in complex with the human nucleotide excision repair protein hHR23A.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
25 11 2021
Historique:
received: 01 07 2020
accepted: 26 10 2021
entrez: 26 11 2021
pubmed: 27 11 2021
medline: 31 12 2021
Statut: epublish

Résumé

HIV-1 Vpr is a prototypic member of a large family of structurally related lentiviral virulence factors that antagonize various aspects of innate antiviral immunity. It subverts host cell DNA repair and protein degradation machineries by binding and inhibiting specific post-replication repair enzymes, linking them via the DCAF1 substrate adaptor to the Cullin 4 RING E3 ligase (CRL4

Identifiants

pubmed: 34824204
doi: 10.1038/s41467-021-27009-w
pii: 10.1038/s41467-021-27009-w
pmc: PMC8617076
doi:

Substances chimiques

DNA-Binding Proteins 0
RAD23B protein, human 0
vpr Gene Products, Human Immunodeficiency Virus 0
vpr protein, Human immunodeficiency virus 1 0
RAD23A protein, human 156533-33-4
XPC protein, human 156533-34-5
Ubiquitin-Protein Ligases EC 2.3.2.27
DCAF1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

6864

Subventions

Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NIAID NIH HHS
ID : P50 AI150481
Pays : United States
Organisme : NIH HHS
ID : S10 OD023481
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Sauter, D. & Kirchhoff, F. Multilayered and versatile inhibition of cellular antiviral factors by HIV and SIV accessory proteins. Cytokine Growth Factor Rev. 40, 3–12 (2018).
pubmed: 29526437 doi: 10.1016/j.cytogfr.2018.02.005
Herate, C. et al. Uracil DNA glycosylase interacts with the p32 subunit of the replication protein A complex to modulate HIV-1 reverse transcription for optimal virus dissemination. Retrovirology 13, 26 (2016).
pubmed: 27068393 pmcid: 4828845 doi: 10.1186/s12977-016-0257-x
Vermeire, J. et al. HIV triggers a cGAS-dependent, Vpu- and Vpr-regulated Type I Interferon response in CD4(+) T cells. Cell Rep. 17, 413–424 (2016).
pubmed: 27705790 doi: 10.1016/j.celrep.2016.09.023
Yan, J., Shun, M. C., Zhang, Y., Hao, C. & Skowronski, J. HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells. Proc. Natl Acad. Sci. USA 116, 9568–9577 (2019).
pubmed: 31019079 pmcid: 6511057 doi: 10.1073/pnas.1818401116
Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935–944 (1995).
pubmed: 7531918 doi: 10.1006/viro.1995.1016
Malim, M. H. & Emerman, M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3, 388–398 (2008).
pubmed: 18541215 doi: 10.1016/j.chom.2008.04.008
Collins, D. R. & Collins, K. L. HIV-1 accessory proteins adapt cellular adaptors to facilitate immune evasion. PLoS Pathog. 10, e1003851 (2014).
pubmed: 24465204 pmcid: 3900642 doi: 10.1371/journal.ppat.1003851
Tristem, M., Purvis, A. & Quicke, D. L. Complex evolutionary history of primate lentiviral vpr genes. Virology 240, 232–237 (1998).
pubmed: 9454696 doi: 10.1006/viro.1997.8929
Sharp, P. M., Bailes, E., Stevenson, M., Emerman, M. & Hahn, B. H. Gene acquisition in HIV and SIV. Nature 383, 586–587 (1996).
pubmed: 8857532 doi: 10.1038/383586a0
Peeters, M. & Courgnaud, V. Overview of primate lentiviruses and their evolution in non-human primates in Africa. In HIV Sequence Compendium (eds Kuiken, C. et al.) 2–23 (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2002).
Le Rouzic, E. et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6, 182–188 (2007).
pubmed: 17314515 doi: 10.4161/cc.6.2.3732
Romani, B. & Cohen, E. A. Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr. Opin. Virol. 2, 755–763 (2012).
pubmed: 23062609 pmcid: 3955192 doi: 10.1016/j.coviro.2012.09.010
Hrecka, K. et al. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc. Natl Acad. Sci. USA 104, 11778–11783 (2007).
pubmed: 17609381 pmcid: 1906728 doi: 10.1073/pnas.0702102104
Selig, L. et al. Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J. Virol. 71, 4842–4846 (1997).
pubmed: 9151883 pmcid: 191711 doi: 10.1128/jvi.71.6.4842-4846.1997
Ahn, J. et al. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J. Biol. Chem. 285, 37333–37341 (2010).
pubmed: 20870715 pmcid: 2988339 doi: 10.1074/jbc.M110.133181
Laguette, N. et al. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156, 134–145 (2014).
pubmed: 24412650 doi: 10.1016/j.cell.2013.12.011
Zhou, X., DeLucia, M. & Ahn, J. SLX4-SLX1 protein-independent down-regulation of MUS81-EME1 protein by HIV-1 viral protein R (Vpr). J. Biol. Chem. 291, 16936–16947 (2016).
pubmed: 27354282 pmcid: 5016100 doi: 10.1074/jbc.M116.721183
Lahouassa, H. et al. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages. Proc. Natl Acad. Sci. USA 113, 5311–5316 (2016).
pubmed: 27114546 pmcid: 4868422 doi: 10.1073/pnas.1600485113
Hrecka, K. et al. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc. Natl Acad. Sci. USA 113, E3921–E3930 (2016).
pubmed: 27335459 pmcid: 4941427 doi: 10.1073/pnas.1605023113
Zhou, X. et al. HIV-1 Vpr protein directly loads helicase-like transcription factor (HLTF) onto the CRL4-DCAF1 E3 ubiquitin ligase. J. Biol. Chem. 292, 21117–21127 (2017).
pubmed: 29079575 pmcid: 5743084 doi: 10.1074/jbc.M117.798801
Yan, J. et al. HIV-1 Vpr reprograms CLR4(DCAF1) E3 ubiquitin ligase to antagonize exonuclease 1-mediated restriction of HIV-1 infection. mBio 9, e01732–18 (2018).
Lv, L. et al. Vpr targets TET2 for degradation by CRL4(VprBP) E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Mol. Cell 70, 961–970e5 (2018).
pubmed: 29883611 pmcid: 6071318 doi: 10.1016/j.molcel.2018.05.007
Wu, Y. et al. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nat. Struct. Mol. Biol. 23, 933–940 (2016).
pubmed: 27571178 pmcid: 5385928 doi: 10.1038/nsmb.3284
Hansen, E. C. et al. Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. Elife 5, e18447 (2016).
Withers-Ward, E. S. et al. Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J. Virol. 71, 9732–9742 (1997).
pubmed: 9371639 pmcid: 230283 doi: 10.1128/jvi.71.12.9732-9742.1997
Gragerov, A., Kino, T., Ilyina-Gragerova, G., Chrousos, G. P. & Pavlakis, G. N. HHR23A, the human homologue of the yeast repair protein RAD23, interacts specifically with Vpr protein and prevents cell cycle arrest but not the transcriptional effects of Vpr. Virology 245, 323–330 (1998).
pubmed: 9636371 doi: 10.1006/viro.1998.9138
Withers-Ward, E. S., Mueller, T. D., Chen, I. S. & Feigon, J. Biochemical and structural analysis of the interaction between the UBA(2) domain of the DNA repair protein HHR23A and HIV-1 Vpr. Biochemistry 39, 14103–14112 (2000).
pubmed: 11087358 doi: 10.1021/bi0017071
Yokoi, M. & Hanaoka, F. Two mammalian homologs of yeast Rad23, HR23A and HR23B, as multifunctional proteins. Gene 597, 1–9 (2017).
pubmed: 27771451 doi: 10.1016/j.gene.2016.10.027
Sugasawa, K. Mechanism and regulation of DNA damage recognition in mammalian nucleotide excision repair. Enzymes 45, 99–138 (2019).
pubmed: 31627884 doi: 10.1016/bs.enz.2019.06.004
Cattoglio, C. et al. Functional and mechanistic studies of XPC DNA-repair complex as transcriptional coactivator in embryonic stem cells. Proc. Natl Acad. Sci. USA 112, E2317–E2326 (2015).
pubmed: 25901318 pmcid: 4426448 doi: 10.1073/pnas.1505569112
Bidon, B. et al. XPC is an RNA polymerase II cofactor recruiting ATAC to promoters by interacting with E2F1. Nat. Commun. 9, 2610 (2018).
pubmed: 29973595 pmcid: 6031651 doi: 10.1038/s41467-018-05010-0
Semer, M. et al. DNA repair complex licenses acetylation of H2A.Z.1 by KAT2A during transcription. Nat. Chem. Biol. 15, 992–1000 (2019).
pubmed: 31527837 doi: 10.1038/s41589-019-0354-y
Schauber, C. et al. Rad23 links DNA repair to the ubiquitin/proteasome pathway. Nature 391, 715–718 (1998).
pubmed: 9490418 doi: 10.1038/35661
Shi, Y. et al. Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome. Science 351, 831–841 (2016).
Ortolan, T. G. et al. The DNA repair protein rad23 is a negative regulator of multi-ubiquitin chain assembly. Nat. Cell Biol. 2, 601–608 (2000).
pubmed: 10980700 doi: 10.1038/35023547
Morellet, N., Bouaziz, S., Petitjean, P. & Roques, B. P. NMR structure of the HIV-1 regulatory protein VPR. J. Mol. Biol. 327, 215–227 (2003).
pubmed: 12614620 doi: 10.1016/S0022-2836(03)00060-3
Jung, J. et al. Binding of HIV-1 Vpr protein to the human homolog of the yeast DNA repair protein RAD23 (hHR23A) requires its xeroderma pigmentosum complementation group C binding (XPCB) domain as well as the ubiquitin-associated 2 (UBA2) domain. J. Biol. Chem. 289, 2577–2588 (2014).
pubmed: 24318982 doi: 10.1074/jbc.M113.534453
Dieckmann, T. et al. Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nat. Struct. Biol. 5, 1042–1047 (1998).
pubmed: 9846873 doi: 10.1038/4220
Walters, K. J., Lech, P. J., Goh, A. M., Wang, Q. & Howley, P. M. DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc. Natl Acad. Sci. USA 100, 12694–12699 (2003).
pubmed: 14557549 pmcid: 240680 doi: 10.1073/pnas.1634989100
Kamionka, M. & Feigon, J. Structure of the XPC binding domain of hHR23A reveals hydrophobic patches for protein interaction. Protein Sci. 13, 2370–2377 (2004).
pubmed: 15322280 pmcid: 2280024 doi: 10.1110/ps.04824304
Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D 60, 2210–2221 (2004).
pubmed: 15572774 doi: 10.1107/S0907444904016427
Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368–380 (2012).
pubmed: 22505257 pmcid: 3322596 doi: 10.1107/S0907444911056058
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
pubmed: 15572765 doi: 10.1107/S0907444904019158
Di Marzio, P., Choe, S., Ebright, M., Knoblauch, R. & Landau, N. R. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69, 7909–7916 (1995).
pubmed: 7494303 pmcid: 189735 doi: 10.1128/jvi.69.12.7909-7916.1995
Greenwood, E. J. D. et al. Promiscuous targeting of cellular proteins by Vpr drives systems-level proteomic remodeling in HIV-1 infection. Cell Rep. 27, 1579–1596 e7 (2019).
pubmed: 31042482 pmcid: 6506760 doi: 10.1016/j.celrep.2019.04.025
Mansky, L. M. et al. Interaction of human immunodeficiency virus type 1 Vpr with the HHR23A DNA repair protein does not correlate with multiple biological functions of Vpr. Virology 282, 176–185 (2001).
pubmed: 11259200 doi: 10.1006/viro.2000.0791
Zhu, Q., Wani, G., Wani, M. A. & Wani, A. A. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. Cancer Res. 61, 64–70 (2001).
pubmed: 11196199
Min, J. H. & Pavletich, N. P. Recognition of DNA damage by the Rad4 nucleotide excision repair protein. Nature 449, 570–575 (2007).
pubmed: 17882165 doi: 10.1038/nature06155
Mansky, L. M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391–400 (1996).
pubmed: 8806523 doi: 10.1006/viro.1996.0436
Hu, W. S. & Hughes, S. H. HIV-1 reverse transcription. Cold Spring Harb. Perspect. Med. 2, a006882 (2012).
Bouhamdan, M. et al. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70, 697–704 (1996).
pubmed: 8551605 pmcid: 189869 doi: 10.1128/jvi.70.2.697-704.1996
Weil, A. F. et al. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc. Natl Acad. Sci. USA 110, E448–E457 (2013).
pubmed: 23341616 pmcid: 3568341 doi: 10.1073/pnas.1219702110
Poon, B. & Chen, I. S. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J. Virol. 77, 3962–3972 (2003).
pubmed: 12634356 pmcid: 150668 doi: 10.1128/JVI.77.7.3962-3972.2003
Cohen, E. A. et al. Identification of HIV-1 vpr product and function. J. Acquir. Immune Defic. Syndr. (1988) 3, 11–18 (1990).
Kino, T. et al. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J. Exp. Med. 189, 51–62 (1999).
pubmed: 9874563 pmcid: 1887689 doi: 10.1084/jem.189.1.51
Tanaka, M. & Herr, W. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60, 375–386 (1990).
pubmed: 2302733 doi: 10.1016/0092-8674(90)90589-7
Kabsch, W. Xds. Acta Crystallogr. D 66, 125–132 (2010).
pubmed: 20124692 pmcid: 2815665 doi: 10.1107/S0907444909047337
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
doi: 10.1007/BF00197809
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
pubmed: 15815974 doi: 10.1002/prot.20449
Schwieters, C. D., Kuszewski, J. J., Tjandra, N. & Clore, G. M. The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).
pubmed: 12565051 doi: 10.1016/S1090-7807(02)00014-9
Schwieters, C. D., Kuszewski, J. J. & Marius Clore, G. Using Xplor–NIH for NMR molecular structure determination. Prog. Nucl. Magn. Reson. Spectrosc. 48, 47–62 (2006).
doi: 10.1016/j.pnmrs.2005.10.001
Cornilescu, G., Delaglio, F. & Bax, A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 13, 289–302 (1999).
pubmed: 10212987 doi: 10.1023/A:1008392405740
Brunger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905–921 (1998).
pubmed: 9757107 doi: 10.1107/S0907444998003254
Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477–486 (1996).
pubmed: 9008363 doi: 10.1007/BF00228148
Koradi, R., Billeter, M. & Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 29–32 (1996). 51-5.
doi: 10.1016/0263-7855(96)00009-4
Braganza, A. et al. UBE3B is a calmodulin-regulated, mitochondrion-associated E3 ubiquitin ligase. J. Biol. Chem. 292, 2470–2484 (2017).
pubmed: 28003368 doi: 10.1074/jbc.M116.766824
Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551–3567 (1999).
pubmed: 10612281 doi: 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2
Graham, F. L. & van der Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456–467 (1973).
pubmed: 4705382 doi: 10.1016/0042-6822(73)90341-3

Auteurs

In-Ja L Byeon (IL)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Guillermo Calero (G)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. guc9@pitt.edu.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. guc9@pitt.edu.

Ying Wu (Y)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Chang H Byeon (CH)

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Jinwon Jung (J)

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
ABL Bio Inc., 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.

Maria DeLucia (M)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Xiaohong Zhou (X)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Simon Weiss (S)

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Jinwoo Ahn (J)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Caili Hao (C)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Molecular Biology and Microbiology, Case Western Reserve School of Medicine, Cleveland, OH, USA.

Jacek Skowronski (J)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Molecular Biology and Microbiology, Case Western Reserve School of Medicine, Cleveland, OH, USA.

Angela M Gronenborn (AM)

Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. amg100@pitt.edu.
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. amg100@pitt.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH